At1g67455 Antibody

FAQs for Researchers on AT1R Antibodies in Academic Research

Advanced Research Questions

How should experimental models be designed to study AT1R antibody-induced pathologies like dermal fibrosis?

• Methodological Answer:

  • Use AT1R-immunized murine models: Inject C57BL/6J mice with membrane-embedded human AT1R to induce skin/lung inflammation and fibrosis .

  • Include T/B cell-deficient mice: Differentiate antibody-mediated effects from adaptive immune contributions (e.g., CD4+ T cell dependency) .

  • Apply monoclonal AT1R antibodies: Validate pathogenicity via passive transfer into wild-type vs. AT1R knockout mice .

What methodologies resolve contradictions in AT1R antibody specificity across commercial products?

• Data Table: Specificity Challenges in Commercial AT1R Antibodies

  Antibody (Vendor)	Key Issues	Recommended Use Case
  sc-1173 (Santa Cruz)	Binds nuclear/cytoplasmic antigens in non-transfected cells	Avoid for IHC in neural tissues
  AB15552 (Millipore)	Detects 43 kDa band in knockout tissues	Use with radioligand binding controls
  AAR-011 (Alomone)	Fails to detect hypothalamic AT1R	Limited to kidney/liver studies

How do functionally active AT1R antibodies influence disease severity in conditions like COVID-19?

• Methodological Answer:

  • Stratify patients by AT1R antibody levels: In COVID-19, anti-AT1R positivity (≥10 U/mL) correlates with reduced hospitalization risk (14.86% positivity in patients vs. 29.46% in controls) .

  • Use competitive inhibition assays: Measure antibody interference with angiotensin II binding to assess protective vs. pathogenic roles .

  • Pair with cytokine profiling: Link AT1R antibody levels to IL-8 or TGF-β pathways in longitudinal cohorts .

Key Considerations for Experimental Design

• Antibody Validation: Always include knockout controls and orthogonal assays .

• Assay Selection: Prioritize functional assays (e.g., luminometric bioassays) over ELISA for clinical relevance .

• Pathway Analysis: Combine AT1R antibody data with downstream markers (e.g., Smad2/3 phosphorylation in fibrosis models) .